By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Astellas Pharma Canada, Inc. 

675 Cochrane Drive, Suite 500
West Tower
Markham  Ontario  L3R 0B8  U.S.A.
Phone: 905-470-7990 or 1-800-575-1382 Fax: 905-470-7799



Company News
World Anti-Doping Agency And Astellas Pharma Canada, Inc. Announce Global Initiative To Prevent Misuse And Abuse Of Medicines For Doping In Sports 10/14/2016 11:54:32 AM
Astellas Pharma Canada, Inc. Release: Dr. Kathryn Tinckam Named As Recipient Of Inaugural Astellas And Canadian Society Of Transplantation Clinical Research Grant 10/13/2016 7:39:02 AM
Astellas Pharma Canada, Inc. And The CNTRP Continue Partnership And Commitment To Canadian Research Innovation 4/27/2016 6:17:32 AM
Astellas Pharma Canada, Inc. Introduces Myrbetriq™, a New Class of Treatment for Canadian Patients With Overactive Bladder 4/10/2013 9:51:04 AM
Astellas Pharma Canada, Inc. Receives a Notice of Compliance From Health Canada for Myrbetriq™ (Mirabegron) 3/8/2013 9:42:54 AM
Canadian Urological Association Partners with Astellas Pharma Canada, Inc. 3/29/2012 8:46:41 AM
Astellas Pharma Canada, Inc. (JOBS) and Theravance, Inc. (THRX) (JOBS) Announce Approval of VIBATIV(TM) in Canada for the Treatment of Complicated Skin and Skin Structure Infections 10/1/2009 6:33:49 AM
Simple Blood Test to Identify Organ Rejection; Astellas Pharma Canada, Inc. Joins the PROOF Centre of Excellence to Fund Innovative Research 7/23/2009 10:58:22 AM
Astellas Adds CNS Therapy Area Leader to Global R&D Team 6/4/2009 9:12:41 AM
Astellas Pharma Canada, Inc. Release: Solifenacin Shows Superior Tolerability Compared to Oxybutynin Immediate-Release (IR) 5/1/2009 12:13:41 PM